TScan Therapeutics Inc. (NASDAQ: TCRX) has experienced a decline in its stock price by -0.82 compared to its previous closing price of 2.43. However, the company has seen a fall of -24.69% in its stock price over the last five trading days.
Is It Worth Investing in TScan Therapeutics Inc. (NASDAQ: TCRX) Right Now?
There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
The average price estimated by analysts for TCRX is $10.50, which is $8.09 above than the current price. The public float for TCRX is 17.61M, and at present, short sellers hold a 2.37% of that float. The average trading volume of TCRX on May 26, 2023 was 1.35M shares.
TCRX’s Market Performance
The stock of TScan Therapeutics Inc. (TCRX) has seen a -24.69% decrease in the past week, with a 10.16% rise in the past month, and a -19.40% fall in the past quarter. The volatility ratio for the week is 17.01%, and the volatility levels for the past 30 days are at 24.15% for TCRX. The simple moving average for the past 20 days is -20.59% for TCRX’s stock, with a -7.11% simple moving average for the past 200 days.
TCRX Trading at -8.25% from the 50-Day Moving Average
After a stumble in the market that brought TCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.03% of loss for the given period.
Volatility was left at 24.15%, however, over the last 30 days, the volatility rate increased by 17.01%, as shares surge +4.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.54% lower at present.
During the last 5 trading sessions, TCRX fell by -25.94%, which changed the moving average for the period of 200-days by -42.89% in comparison to the 20-day moving average, which settled at $3.04. In addition, TScan Therapeutics Inc. saw 55.48% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TCRX starting from Silver Brian M., who purchase 3,158 shares at the price of $1.56 back on Dec 28. After this action, Silver Brian M. now owns 32,885 shares of TScan Therapeutics Inc., valued at $4,941 using the latest closing price.
Silver Brian M., the Chief Financial Officer of TScan Therapeutics Inc., purchase 2,842 shares at $1.50 during a trade that took place back on Dec 27, which means that Silver Brian M. is holding 29,727 shares at $4,276 based on the most recent closing price.
Stock Fundamentals for TCRX
Current profitability levels for the company are sitting at:
- -492.32 for the present operating margin
- +62.05 for the gross margin
The net margin for TScan Therapeutics Inc. stands at -489.26. The total capital return value is set at -37.84, while invested capital returns managed to touch -38.18. Equity return is now at value -68.20, with -42.10 for asset returns.
Based on TScan Therapeutics Inc. (TCRX), the company’s capital structure generated 86.47 points at debt to equity in total, while total debt to capital is 46.37. Total debt to assets is 43.19, with long-term debt to equity ratio resting at 82.77. Finally, the long-term debt to capital ratio is 44.39.
When we switch over and look at the enterprise to sales, we see a ratio of 0.84, with the company’s debt to enterprise value settled at 26.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.17.
Conclusion
In summary, TScan Therapeutics Inc. (TCRX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
